• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-1MEF filed by Palisade Bio Inc.

    10/1/25 8:55:40 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PALI alert in real time by email
    S-1MEF 1 forms-1mef.htm S-1MEF

     

    As filed with the Securities and Exchange Commission on October 1, 2025.

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM S-1

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    Palisade Bio, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

             
    Delaware   2834   52-2007292
    (State or Other Jurisdiction of
    Incorporation or Organization)
      (Primary Standard Industrial
    Classification Code Number)
      (I.R.S. Employer
    Identification Number)

     

    Palisade Bio, Inc.

    1902 Wright Place, Suite 200

    Carlsbad, CA 92008

    (858) 704-4900

    (Address, including zip code, and telephone number, including area code of registrant’s principal executive offices)

     

     

     

    JD Finley, Chief Executive Officer

    Palisade Bio, Inc.

    1902 Wright Place, Suite 200

    Carlsbad, CA 92008

    (858) 704-4900 

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

     

    Jeffrey C. Thacker   Michael F. Nertney

    Ryan J. Gunderson

    John E. Maciejewski

    Gunderson Dettmer Stough Villeneuve

    Franklin & Hachigian, LLP

    3570 Carmel Mountain Road, Suite 200

    San Diego, California 92130

    (858) 436-8000

     

    Ellenoff Grossman & Schole LLP

    1345 Avenue of the Americas

    New York, New York 10105

    (212) 370-1300

     

     

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (File No. 333-290568)

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

                 
    Large accelerated filer   ☐   Accelerated filer   ☐
    Non-accelerated filer   ☒   Smaller reporting company   ☒
            Emerging growth company   ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

    This registration statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) of the Securities Act of 1933, as amended.

     

     

     

     

     

     

    EXPLANATORY NOTE AND INCORPORATION BY REFERENCE

     

    This Registration Statement is being filed pursuant to Rule 462(b) as promulgated under the Securities Act of 1933, as amended, and includes the registration statement facing page, this page, the signature page, an exhibit index and the required opinion and consents solely to register up to an aggregate of $24,518,000 in (i) additional shares of our common stock, par value $0.01 per share (the “common stock”), (ii) pre-funded warrants to purchase shares of our common stock, (iii) warrants to purchase shares of our common stock to be issued to the representative of the underwriters in the offering (“Representative Warrants”); and (iv) shares of common stock underlying the pre-funded warrants and Representative Warrants. The contents of the Registration Statement on Form S-1 (Registration No. 333-290568), as amended, including the exhibits and power of attorney thereto, which was declared effective by the Securities and Exchange Commission on September 30, 2025, are incorporated by reference in this Registration Statement.

     

    The required opinions and consents are listed on the Exhibit Index attached hereto and are filed herewith.

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit
    Number
       
      Description of document
         
    5.1   Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP.
         
    23.1   Consent of Baker Tilly US, LLP, Independent Registered Public Accounting Firm.
         
    23.2   Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (included in Exhibit 5.1).
         
    24.1   Power of Attorney (incorporated by reference to the signature page of the Prior Registration Statement on Form S-1 (File No. 333-290568), filed with the Securities and Exchange Commission on September 29, 2025 and incorporated herein by reference).
         
    107   Filing Fee Table.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Carlsbad, State of California on October 1, 2025.

     

      Palisade Bio, Inc.
         
      By:

    /s/ J.D. Finley

        J.D. Finley
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on the dates indicated.

     

    Signature   Title   Date
         
    /s/ J.D. Finley   Chief Executive Officer and Director   October 1, 2025
    J.D. Finley   (Principal Executive Officer)    
         
    /s/ J. D. Finley   Chief Financial Officer   October 1, 2025
    J.D. Finley   (Principal Financial Officer and Principal Accounting Officer)    
         
    *   Chairman of the Board and Director   October 1, 2025
    Donald A. Williams        
         
    *   Director   October 1, 2025
    Binxian Wei        
         
    *   Director   October 1, 2025
    Emil Chuang        

     

    *By:

    /s/ J.D. Finley

     
      J.D. Finley  
      Attorney-in-Fact  

     

     

     

    Get the next $PALI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PALI

    DatePrice TargetRatingAnalyst
    1/9/2026$7.00Buy
    B. Riley Securities
    12/29/2025$25.00Overweight
    Piper Sandler
    2/2/2022$5.00Buy
    Ladenburg Thalmann
    8/31/2021$7.00Buy
    Maxim Group
    More analyst ratings

    $PALI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Williams Donald Allen bought $4,863 worth of Comon Stock (1,000 units at $4.86) (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    5/29/24 3:47:14 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PALI
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Palisade Bio Inc.

    SCHEDULE 13G - PALISADE BIO, INC. (0001357459) (Subject)

    1/29/26 11:02:59 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Palisade Bio Inc.

    SCHEDULE 13G - PALISADE BIO, INC. (0001357459) (Subject)

    12/8/25 11:46:25 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - PALISADE BIO, INC. (0001357459) (Filer)

    12/4/25 4:40:01 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PALI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Jones Mitchell Lawrence

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/11/26 5:34:45 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by CEO, CFO Finley John David

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/11/26 5:32:05 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PALI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium

    Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast here Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET. Th

    2/9/26 9:00:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

    Virtual presentation scheduled for Thursday, February 26th at 12:40 PM ET Access the webcast here Carlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25–26, 2026. The Company's virtual presentation is scheduled for Thur

    2/5/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PALI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Palisade Bio with a new price target

    Piper Sandler initiated coverage of Palisade Bio with a rating of Overweight and set a new price target of $25.00

    12/29/25 7:10:24 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ladenburg Thalmann initiated coverage on Palisade Bio with a new price target

    Ladenburg Thalmann initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/2/22 7:38:44 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PALI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Palisade Bio Inc.

    SC 13G - PALISADE BIO, INC. (0001357459) (Subject)

    11/14/24 3:35:13 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

    SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

    2/14/24 2:54:03 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

    SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

    2/13/24 8:10:04 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PALI
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

    Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, MD, AGAF as Vice President, Clinical Development. Dr. Izanec is a physician–scientist with over two decades of clinical and drug development leadership spanning immunology, neuroscience, and gastr

    12/2/25 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

    Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications Company remains focused on advancing PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease, with Phase 2 IND submission planned for H1 2026 Carlsbad, CA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing precision therapies for autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Sharon Skare, PhD(c) as Vice President, Global Head of Clinical Operations. Ms. Skare brings mor

    10/28/25 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PALI
    Financials

    Live finance-specific insights

    View All

    Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

    Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EDT CARLSBAD, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN.) These data are featured today at the Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 202

    3/16/22 8:00:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care